JP2015508828A5 - - Google Patents

Download PDF

Info

Publication number
JP2015508828A5
JP2015508828A5 JP2014560091A JP2014560091A JP2015508828A5 JP 2015508828 A5 JP2015508828 A5 JP 2015508828A5 JP 2014560091 A JP2014560091 A JP 2014560091A JP 2014560091 A JP2014560091 A JP 2014560091A JP 2015508828 A5 JP2015508828 A5 JP 2015508828A5
Authority
JP
Japan
Prior art keywords
amino
pyridin
pyrimidin
optionally substituted
fluorophenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014560091A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015508828A (ja
JP6068515B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/028622 external-priority patent/WO2013130976A1/en
Publication of JP2015508828A publication Critical patent/JP2015508828A/ja
Publication of JP2015508828A5 publication Critical patent/JP2015508828A5/ja
Application granted granted Critical
Publication of JP6068515B2 publication Critical patent/JP6068515B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014560091A 2012-03-01 2013-03-01 セリン/トレオニンキナーゼ阻害剤 Active JP6068515B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261605523P 2012-03-01 2012-03-01
US61/605,523 2012-03-01
PCT/US2013/028622 WO2013130976A1 (en) 2012-03-01 2013-03-01 Serine/threonine kinase inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015179810A Division JP2016027053A (ja) 2012-03-01 2015-09-11 セリン/トレオニンキナーゼ阻害剤

Publications (3)

Publication Number Publication Date
JP2015508828A JP2015508828A (ja) 2015-03-23
JP2015508828A5 true JP2015508828A5 (enExample) 2015-11-05
JP6068515B2 JP6068515B2 (ja) 2017-01-25

Family

ID=47892024

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2014560091A Active JP6068515B2 (ja) 2012-03-01 2013-03-01 セリン/トレオニンキナーゼ阻害剤
JP2015179810A Withdrawn JP2016027053A (ja) 2012-03-01 2015-09-11 セリン/トレオニンキナーゼ阻害剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015179810A Withdrawn JP2016027053A (ja) 2012-03-01 2015-09-11 セリン/トレオニンキナーゼ阻害剤

Country Status (36)

Country Link
US (4) US8697715B2 (enExample)
EP (2) EP2820009B1 (enExample)
JP (2) JP6068515B2 (enExample)
KR (1) KR102093526B1 (enExample)
CN (2) CN104507926B (enExample)
AR (2) AR090220A1 (enExample)
AU (1) AU2013225737B2 (enExample)
BR (1) BR112014021634B1 (enExample)
CA (1) CA2866086C (enExample)
CL (1) CL2014002301A1 (enExample)
CO (1) CO7081155A2 (enExample)
CR (1) CR20140413A (enExample)
CY (1) CY1120172T1 (enExample)
DK (2) DK3321262T3 (enExample)
ES (2) ES2857649T3 (enExample)
HR (2) HRP20180591T1 (enExample)
HU (2) HUE053994T2 (enExample)
IL (2) IL234376A (enExample)
LT (2) LT3321262T (enExample)
MX (1) MX354675B (enExample)
MY (1) MY191936A (enExample)
NO (1) NO2945854T3 (enExample)
NZ (1) NZ700314A (enExample)
PE (1) PE20150666A1 (enExample)
PH (3) PH12015501654A1 (enExample)
PL (2) PL2820009T3 (enExample)
PT (2) PT3321262T (enExample)
RS (2) RS61500B1 (enExample)
RU (1) RU2650501C2 (enExample)
SG (1) SG11201405356QA (enExample)
SI (2) SI2820009T1 (enExample)
SM (1) SMT201800282T1 (enExample)
TW (1) TWI589569B (enExample)
UA (1) UA116774C2 (enExample)
WO (1) WO2013130976A1 (enExample)
ZA (2) ZA201406688B (enExample)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9133187B2 (en) 2011-02-28 2015-09-15 Array Biopharma Inc. Serine/threonine kinase inhibitors
KR101979042B1 (ko) 2011-08-04 2019-05-15 어레이 바이오파마 인크. 세린/트레오닌 키나제 억제제로서의 퀴나졸린 화합물
DK3321262T3 (da) * 2012-03-01 2021-01-25 Array Biopharma Inc Serin-/threoninkinasehæmmere
CN104271569B (zh) * 2012-05-03 2016-08-24 霍夫曼-拉罗奇有限公司 作为lrrk2调节剂的吡唑氨基嘧啶衍生物
JP6378182B2 (ja) 2012-08-27 2018-08-22 アレイ バイオファーマ、インコーポレイテッド 過剰増殖性│疾患の処置のためのセリン/スレオニンキナーゼ阻害剤
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
CA2884766A1 (en) 2012-10-16 2014-04-24 Daniel Jon Burdick Serine/threonine kinase inhibitors
WO2017156493A1 (en) 2016-03-11 2017-09-14 Denali Therapeutics Inc. Compounds, compositions, and methods
US9532987B2 (en) * 2013-09-05 2017-01-03 Genentech, Inc. Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases
PE20161073A1 (es) 2013-11-01 2016-10-30 Novartis Ag Amino-heteroaril-benzamidas como inhibidores de cinasa
AU2014360455B2 (en) * 2013-12-06 2018-05-10 Genentech, Inc. Serine/threonine kinase inhibitors
BR112016015235A2 (pt) * 2013-12-30 2017-08-08 Genentech Inc Composto, composição farmacêutica, método de inibição da atividade da proteína quinase erk e método de tratamento
EP3089980B1 (en) 2013-12-30 2018-01-31 Array Biopharma, Inc. Serine/threonine kinase inhibitors
CN106459042B (zh) 2014-04-02 2019-06-28 英特穆恩公司 抗纤维化吡啶酮类
HRP20191306T1 (hr) * 2014-04-09 2019-10-18 Genentech, Inc. Postupak proizvodnje lijekova
TWI704151B (zh) 2014-12-22 2020-09-11 美商美國禮來大藥廠 Erk抑制劑
CN107074874B (zh) 2014-12-22 2019-04-23 伊莱利利公司 Erk抑制剂
CN107849046B (zh) * 2015-06-03 2020-06-12 常州捷凯医药科技有限公司 作为erk抑制剂的杂环化合物
CA2987963C (en) * 2015-06-03 2023-01-24 Js Innopharm (Shanghai) Ltd. Heterocyclic compounds for treating psoriasis
ES2989326T3 (es) 2015-10-21 2024-11-26 Otsuka Pharma Co Ltd Compuestos de benzolactama como inhibidores de la proteína cinasa
EP3365335B1 (en) * 2015-10-23 2024-02-14 Array Biopharma, Inc. 2-aryl- and 2-heteroaryl-substituted 2-pyridazin-3(2h)-one compounds as inhibitors of fgfr tyrosine kinases
WO2017080979A1 (en) 2015-11-09 2017-05-18 Astrazeneca Ab Dihydroimidazopyrazinone derivatives useful in the treatment of cancer
US11214565B2 (en) 2015-11-20 2022-01-04 Denali Therapeutics Inc. Compound, compositions, and methods
CN109072311A (zh) 2016-04-15 2018-12-21 豪夫迈·罗氏有限公司 用于癌症的诊断和治疗方法
SI3472153T1 (sl) 2016-06-16 2022-01-31 Denali Therapeutics Inc. Pirimidin-2-ilamino-1H-pirazoli kot zaviralci LRRK2 za uporabo pri zdravljenju nevrodegenerativnih motenj
GB201706327D0 (en) 2017-04-20 2017-06-07 Otsuka Pharma Co Ltd A pharmaceutical compound
US11242334B2 (en) 2017-08-22 2022-02-08 Js Innopharm (Shanghai) Ltd. Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof
EP4056556A1 (en) * 2017-08-23 2022-09-14 Sprint Bioscience AB Pyridylpyridone compounds
KR102811888B1 (ko) 2017-09-08 2025-05-27 에프. 호프만-라 로슈 아게 암의 진단 및 치료 방법
CU20200035A7 (es) 2017-11-24 2021-03-11 Novartis Ag Compuestos derivados de piridin-2-ona (6´-oxo-1´,6´dihidro) sustituidos como inhibidores selectivos de alk-2
EP3750880B1 (en) * 2018-02-08 2022-12-21 Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd. Pyrazine-2(1h)-ketone compound acting as fgfr inhibitor
EP3752200A1 (en) 2018-02-13 2020-12-23 Vib Vzw Targeting minimal residual disease in cancer with rxr antagonists
CN112638917B (zh) * 2018-05-22 2023-09-08 捷思英达控股有限公司 作为激酶抑制剂的杂环化合物、包括该杂环化合物的组合物、及其使用方法
JP2022515198A (ja) 2018-12-19 2022-02-17 アレイ バイオファーマ インコーポレイテッド FGFRチロシンキナーゼの阻害剤としての置換ピラゾロ[1,5-a]ピリジン化合物
CN113474337A (zh) 2018-12-19 2021-10-01 奥瑞生物药品公司 作为fgfr抑制剂用于治疗癌症的7-((3,5-二甲氧基苯基)氨基)喹喔啉衍生物
JP2022527744A (ja) * 2019-03-28 2022-06-06 ジエンス ヘンルイ メデイシンカンパニー リミテッド チエノ複素環式誘導体、この誘導体のための調製方法及び医療に関するこの誘導体の使用
WO2020228817A1 (zh) * 2019-05-15 2020-11-19 南京明德新药研发有限公司 Erk抑制剂及其应用
WO2021025407A1 (ko) 2019-08-02 2021-02-11 웰마커바이오 주식회사 옥소-피리딘 융합고리 유도체 및 이를 포함하는 약학적 조성물
WO2022100586A1 (zh) * 2020-11-11 2022-05-19 南京明德新药研发有限公司 一种含氧杂环丁烷的螺环类化合物的晶型、制备方法及其应用
CN115413669B (zh) * 2022-06-14 2024-03-15 湖南大学 激酶抑制剂及其组合剂在提高植物青枯病抗性中的应用
TW202529768A (zh) 2023-09-29 2025-08-01 大陸商德昇濟醫藥(無錫)有限公司 癌症治療的療法

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0672035A1 (en) 1993-10-01 1995-09-20 Novartis AG Pyrimidineamine derivatives and processes for the preparation thereof
DE69434721T2 (de) 1993-10-01 2006-11-09 Novartis Ag Pharmacologisch wirksame pyrimidinderivate und verfahren zu deren herstellung
US5543523A (en) 1994-11-15 1996-08-06 Regents Of The University Of Minnesota Method and intermediates for the synthesis of korupensamines
BR9713863A (pt) 1996-12-05 2000-03-14 Amgen Inc Composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, processos de profilaxia ou tratamento, para abaixar as concentrações no plasma, para diminuir a produção de prostaglandinas, e, para diminuir a atividade de enzima ciclooxigenase
US6602872B1 (en) * 1999-12-13 2003-08-05 Merck & Co., Inc. Substituted pyridazines having cytokine inhibitory activity
KR100521735B1 (ko) 2000-02-25 2005-10-17 에프. 호프만-라 로슈 아게 아데노신 수용체 조절인자
IL152023A0 (en) 2000-04-26 2003-04-10 Eisai Co Ltd Compounds having adenosine a2 receptor antagonism and pharmaceutical compositions containing the same
AU2001273983A1 (en) 2000-05-02 2001-11-12 Lutz F. Tietze Novel prodrugs von 6-hydroxy-2,3-dihydro-1h-indoles, 5-hydroxy-1,2-dihydro-3h-pyrrolo(3,2-e)indoles and 5-hydroxy-1,2-dihydro-3h-benzo(e)indoles as well as of 6-hydroxy-1,2,3,4-tetrahydro-benzo(f)quinoline derivatives for use in selective cancer therapy
WO2002088079A2 (en) 2001-05-01 2002-11-07 Bristol-Myers Squibb Company Dual inhibitors of pde 7 and pde 4
WO2003030909A1 (en) 2001-09-25 2003-04-17 Bayer Pharmaceuticals Corporation 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer
TWI330183B (enExample) * 2001-10-22 2010-09-11 Eisai R&D Man Co Ltd
WO2003057689A1 (en) * 2002-01-02 2003-07-17 Fujisawa Pharmaceutical Co., Ltd. Aminopyrimidine compounds, processes for their preparation and pharmaceutical compositions containing them
ES2334990T3 (es) * 2002-02-14 2010-03-18 Pharmacia Corporation Piridinonas sustituidas como moduladores de p38 map quinasa.
MXPA04011470A (es) * 2002-05-21 2005-02-14 Amgen Inc Compuestos heterociclicos sustituidos y metodos de uso.
GB0215676D0 (en) * 2002-07-05 2002-08-14 Novartis Ag Organic compounds
DE60330485D1 (de) 2002-07-15 2010-01-21 Merck & Co Inc Zur behandlung von diabetes
US20050014753A1 (en) 2003-04-04 2005-01-20 Irm Llc Novel compounds and compositions as protein kinase inhibitors
CL2004002050A1 (es) * 2003-08-13 2005-06-03 Pharmacia Corp Sa Organizada B Compuestos derivados de piridinonas sustituidas; su uso en el tratamiento de afecciones causadas o exacerbadas por actividad p38 map kinasa y/o tnf no regulada, tales como inflamaciones, tumores, sida y otros.
TW200533357A (en) 2004-01-08 2005-10-16 Millennium Pharm Inc 2-(amino-substituted)-4-aryl pyrimidines and related compounds useful for treating inflammatory diseases
US7560464B2 (en) 2004-04-13 2009-07-14 Icagen, Inc. Polycyclic pyrimidines as potassium ion channel modulators
US7429604B2 (en) * 2004-06-15 2008-09-30 Bristol Myers Squibb Company Six-membered heterocycles useful as serine protease inhibitors
JP2008510766A (ja) 2004-08-27 2008-04-10 ゲーペーツェー ビオテック アーゲー ピリミジン誘導体
GB0420722D0 (en) * 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
GB0428514D0 (en) 2004-12-31 2005-02-09 Prosidion Ltd Compounds
EP1871762A2 (en) 2005-04-18 2008-01-02 Neurogen Corporation Subtituted heteroaryl cb1 antagonists
GT200600381A (es) 2005-08-25 2007-03-28 Compuestos organicos
US7572809B2 (en) 2005-12-19 2009-08-11 Hoffmann-La Roche Inc. Isoquinoline aminopyrazole derivatives
CN101415674A (zh) 2006-02-16 2009-04-22 先灵公司 作为erk抑制剂的吡咯烷衍生物
CA2651072A1 (en) 2006-05-01 2007-11-08 Pfizer Products Inc. Substituted 2-amino-fused heterocyclic compounds
DE102006035202A1 (de) 2006-07-29 2008-01-31 Lanxess Deutschland Gmbh Konservierungsmittel auf Basis von Carbonsäureanhydriden
MX2009001913A (es) 2006-08-23 2009-03-06 Pfizer Prod Inc Compuestos de pirimidona como inhibidores de gsk-3.
WO2008039882A1 (en) 2006-09-30 2008-04-03 Sanofi-Aventis U.S. Llc A combination of niacin and a prostaglandin d2 receptor antagonist
JO2985B1 (ar) 2006-12-20 2016-09-05 Takeda Pharmaceuticals Co مثبطات كينازmapk/erk
AU2007336933A1 (en) 2006-12-22 2008-07-03 Novartis Ag Heteroaryl-heteroaryl compounds as CDK inhibitors for the treatment of cancer, inflammation and viral infections
BRPI0806853B1 (pt) 2007-02-01 2018-03-20 Janssen Sciences Ireland Uc Processos e intermediários para preparar um inibidor de protease macrocíclico de hcv
AU2008258508A1 (en) 2007-06-08 2008-12-11 Bayer Cropscience Ag Fungicide heterocyclyl-pyrimidinyl-amino derivatives
EP2200436B1 (en) 2007-09-04 2015-01-21 The Scripps Research Institute Substituted pyrimidinyl-amines as protein kinase inhibitors
MX2010005033A (es) 2007-11-06 2010-05-27 Du Pont Aminas heterociclicas fungicidas.
NZ587504A (en) 2008-02-21 2012-09-28 Merck Sharp & Dohme Benzopyrazole derivatives as ERK inhibitors
US20090246198A1 (en) 2008-03-31 2009-10-01 Takeda Pharmaceutical Company Limited Mapk/erk kinase inhibitors and methods of use thereof
MX2010014572A (es) 2008-06-27 2011-03-24 Novartis Ag Compuestos organicos.
SG10201510696RA (en) 2008-06-27 2016-01-28 Celgene Avilomics Res Inc Heteroaryl compounds and uses thereof
PT2370413E (pt) 2008-12-08 2015-10-23 Arena Pharm Inc Moduladores do recetor da prostaciclina (pgi2) úteis para o tratamento de distúrbios relacionados com o mesmo
DE102009051799B4 (de) 2009-11-03 2021-07-01 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts Bifunktionale Prodrugs und Drugs
DE102009060175A1 (de) 2009-12-23 2011-06-30 Merck Patent GmbH, 64293 Pyrrolo[2,3-d] pyrazin-7-yl-pyrimidin-Verbindungen
JPWO2012020786A1 (ja) * 2010-08-11 2013-10-28 日本新薬株式会社 医薬組成物
US9133187B2 (en) 2011-02-28 2015-09-15 Array Biopharma Inc. Serine/threonine kinase inhibitors
CN102250065B (zh) * 2011-05-20 2015-05-13 浙江海正药业股份有限公司 取代的三嗪苯脲衍生物及其用途
KR101979042B1 (ko) 2011-08-04 2019-05-15 어레이 바이오파마 인크. 세린/트레오닌 키나제 억제제로서의 퀴나졸린 화합물
DK3321262T3 (da) 2012-03-01 2021-01-25 Array Biopharma Inc Serin-/threoninkinasehæmmere
JP6378182B2 (ja) 2012-08-27 2018-08-22 アレイ バイオファーマ、インコーポレイテッド 過剰増殖性│疾患の処置のためのセリン/スレオニンキナーゼ阻害剤
KR102244553B1 (ko) 2013-08-23 2021-04-23 가부시키가이샤 한도오따이 에네루기 켄큐쇼 용량 소자 및 반도체 장치
US9532987B2 (en) * 2013-09-05 2017-01-03 Genentech, Inc. Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases
EP3089980B1 (en) * 2013-12-30 2018-01-31 Array Biopharma, Inc. Serine/threonine kinase inhibitors
BR112016015235A2 (pt) * 2013-12-30 2017-08-08 Genentech Inc Composto, composição farmacêutica, método de inibição da atividade da proteína quinase erk e método de tratamento
HRP20191306T1 (hr) * 2014-04-09 2019-10-18 Genentech, Inc. Postupak proizvodnje lijekova

Similar Documents

Publication Publication Date Title
JP2015508828A5 (enExample)
HRP20210482T1 (hr) Inhibitori serinske/treoninske kinaze
US20240360165A1 (en) Inhibitors of cyclin dependent kinase 7 (cdk7)
JP2017500364A5 (enExample)
AU2018201953A1 (en) Certain amino-pyridazines, compositions thereof, and methods of their use
JP2017502049A5 (enExample)
KR20160106627A (ko) 치료적 억제 화합물
IL258577A (en) 2,4-dihydroxy-nicotinamides as apj agonists
KR102082331B1 (ko) Cot 조정제로서의 6-아미노-퀴놀린-3-카르보니트릴
JP2013527173A5 (enExample)
FI3356344T3 (fi) Mdm2-p53-vuorovaikutuksen isoindolinoniestäjiä, joilla on syövänvastaista aktiivisuutta
JP2016530299A5 (enExample)
EP2763672A1 (en) 1,3-substituted azetidine pde10 inhibitors
JP2014528446A5 (enExample)
JPWO2020165833A5 (enExample)
RU2019117958A (ru) Производные индола, полезные в качестве ингибиторов диацилглицерид-о-ацилтрансферазы 2
KR101898364B1 (ko) 인돌린-2-온 및 1,3-다이하이드로-피롤로[3,2-c]피리딘-2-온 유도체
JPWO2022029573A5 (enExample)
JPWO2021005034A5 (enExample)
JP2018111688A (ja) 医薬組成物
JPWO2017007008A1 (ja) 新規イミド誘導体およびその医薬としての用途
RU2025103751A (ru) Соединения на основе имидазопиридина, их получение и варианты их терапевтического применения
RU2022107496A (ru) Производные гетероциклического пиразола как ингибиторы рецепторной тирозикиназы типа III
HK1225735A1 (zh) 丝氨酸/苏氨酸激酶抑制剂